Pfizer Says New
Insulin Inhaler Available Next Month - Inhaled Diabetes Drug Exubera
Will Cost More But Patients Gain Less Weight
June 10th 2006
In January the Food and Drug Administration (FDA) approved Exubera, an
inhaled insulin drug. Now the drug maker, Pfizer Inc, says they hope to
launch Exubera in the United States next month.
Pfizer, the world’s largest drug maker, expects to market the product
for adults with either Type 1 or Type 2 diabetes. Sales are expected to
top $1 billion a year.
The drug appears safe, according to Reuters. In trials, it has been
able to safely control blood sugar over a two-year period. It is
expected than many Americans will switch to this new method of
introducing insulin into their body.
There are no insulin pills because the compound is destroyed by stomach
acid. This is the reason diabetics have had to rely on injecting
themselves with insulin daily. Exubera will cost more than the current
injectable type. It may cost double or triple the current injectable